SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Item 9 Labs Corp. (INLB) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 23/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — INLB
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.33
Book Value / Share$0.00
Revenue / Share$0.23
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-1.94 |
$341.99K |
$-3.33M |
-972.3% |
| 2014 |
$-6.87 |
$179.49K |
$-17.08M |
-9516.9% |
| 2015 |
$-1.43 |
$113.02K |
$-4.74M |
-4194.5% |
| 2016 |
$-0.82 |
$324.03K |
$-3.13M |
-964.6% |
| 2017 |
$-0.04 |
$243.93K |
$-266.57K |
-109.3% |
| 2018 |
$-0.23 |
$1.38M |
$-642.28K |
-46.7% |
| 2019 |
$-0.17 |
$4.93M |
$-10.63M |
-215.5% |
| 2020 |
$-0.20 |
$8.12M |
$-12.3M |
-151.4% |
| 2021 |
$-0.21 |
$21.94M |
$-16.19M |
-73.8% |
| 2022 |
$-0.33 |
$21.76M |
$-31.14M |
-143.1% |
